The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.

Balance issues with MS make it difficult for columnist Leigh Anne Nelson to navigate stairs and aisles at stadium events.

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Columnist Desiree Lama shares what she wishes she'd been told after her diagnosis of multiple sclerosis at age 17.

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Getting used to living with MS is like trying to cook in a kitchen that's unfamiliar, columnist Ben Hofmeister writes.

Nondrug therapy costs for people with MS in Austria can be high, averaging €136 per month (about $149), according to a study.